Skip to main content
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2003 Sep;62(9):812–816. doi: 10.1136/ard.62.9.812

Initiation of biological agents in patients with ankylosing spondylitis: results of a Delphi study by the ASAS Group

T Pham 1, D van der Heijde 1, A Calin 1, M Khan 1, S van der Linden 1, N Bellamy 1, M Dougados 1
PMCID: PMC1754653  PMID: 12922951

Abstract

Background: There is ample evidence of important symptomatic efficacy of tumour necrosis factor α (TNFα) inhibition in ankylosing spondylitis (AS). Moreover, studies suggest that anti-TNF could be considered as the first disease controlling antirheumatic treatment (DC-ART) for AS.

Objective: To determine precisely which patients with AS are most likely to benefit from anti-TNFα treatment because of the cost and possible long term side effects of such treatment.

Methods: Assessment in Ankylosing Spondylitis (ASAS) members were asked to use a Delphi technique to name the characteristics of patients with AS for whom they would start DC-ART, in three different clinical presentations (isolated axial involvement, peripheral arthritis, enthesitis).

Results: Among the 62 invited ASAS members, more than 50% actively participated in the four phases of definition according to the Delphi technique. For each of the three clinical presentations, a combination of five to six domains was proposed, with an evaluation instrument and a cut off point defining a minimum level of activity for each domain.

Conclusion: This study provides a profile for a patient with AS for considering initiation of biological agents that reflects the opinion of the ASAS members, using a Delphi exercise. Further studies are required to assess their relevance and their consistency with clinical practice.

Full Text

The Full Text of this article is available as a PDF (187.0 KB).

Figure 1.

Figure 1

Delphi technique: second turn results. Domains considered as relevant by the ASAS members in a patient with AS with (A) isolated axial involvement clinical presentation; (B) peripheral arthritis clinical presentation; and (C) enthesitis clinical presentation.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amor B., Dougados M., Khan M. A. Management of refractory ankylosing spondylitis and related spondyloarthropathies. Rheum Dis Clin North Am. 1995 Feb;21(1):117–128. [PubMed] [Google Scholar]
  2. Bathon J. M., Martin R. W., Fleischmann R. M., Tesser J. R., Schiff M. H., Keystone E. C., Genovese M. C., Wasko M. C., Moreland L. W., Weaver A. L. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000 Nov 30;343(22):1586–1593. doi: 10.1056/NEJM200011303432201. [DOI] [PubMed] [Google Scholar]
  3. Boonen A., Chorus A., Miedema H., van der Heijde D., van der Tempel H., van der Linden S. Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis. 2001 Apr;60(4):353–358. doi: 10.1136/ard.60.4.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brandt J., Haibel H., Cornely D., Golder W., Gonzalez J., Reddig J., Thriene W., Sieper J., Braun J. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum. 2000 Jun;43(6):1346–1352. doi: 10.1002/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E. [DOI] [PubMed] [Google Scholar]
  5. Braun J., Brandt J., Listing J., Zink A., Alten R., Golder W., Gromnica-Ihle E., Kellner H., Krause A., Schneider M. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002 Apr 6;359(9313):1187–1193. doi: 10.1016/s0140-6736(02)08215-6. [DOI] [PubMed] [Google Scholar]
  6. Calin A., Garrett S., Whitelock H., Kennedy L. G., O'Hea J., Mallorie P., Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994 Dec;21(12):2281–2285. [PubMed] [Google Scholar]
  7. Dayer Jean-Michel, Krane Stephen M. Anti-TNF-alpha therapy for ankylosing spondylitis--a specific or nonspecific treatment? N Engl J Med. 2002 May 2;346(18):1399–1400. doi: 10.1056/NEJM200205023461811. [DOI] [PubMed] [Google Scholar]
  8. Edmonds J. P., Scott D. L., Furst D. E., Paulus H. E. New classification of antirheumatic drugs. The evolution of a concept. J Rheumatol. 1993 Mar;20(3):585–587. [PubMed] [Google Scholar]
  9. Gorman Jennifer D., Sack Kenneth E., Davis John C., Jr Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002 May 2;346(18):1349–1356. doi: 10.1056/NEJMoa012664. [DOI] [PubMed] [Google Scholar]
  10. Lipsky P. E., van der Heijde D. M., St Clair E. W., Furst D. E., Breedveld F. C., Kalden J. R., Smolen J. S., Weisman M., Emery P., Feldmann M. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000 Nov 30;343(22):1594–1602. doi: 10.1056/NEJM200011303432202. [DOI] [PubMed] [Google Scholar]
  11. Sharp J. T., Strand V., Leung H., Hurley F., Loew-Friedrich I. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum. 2000 Mar;43(3):495–505. doi: 10.1002/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO;2-U. [DOI] [PubMed] [Google Scholar]
  12. Stone M., Salonen D., Lax M., Payne U., Lapp V., Inman R. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol. 2001 Jul;28(7):1605–1614. [PubMed] [Google Scholar]
  13. Van den Bosch F., Kruithof E., Baeten D., De Keyser F., Mielants H., Veys E. M. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis. 2000 Jun;59(6):428–433. doi: 10.1136/ard.59.6.428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Zink A., Listing J., Klindworth C., Zeidler H., German Collaboratrive Arthritis Centres The national database of the German Collaborative Arthritis Centres: I. Structure, aims, and patients. Ann Rheum Dis. 2001 Mar;60(3):199–206. doi: 10.1136/ard.60.3.199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. van der Heijde D., Calin A., Dougados M., Khan M. A., van der Linden S., Bellamy N. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol. 1999 Apr;26(4):951–954. [PubMed] [Google Scholar]
  16. van der Heijde D., van der Linden S., Bellamy N., Calin A., Dougados M., Khan M. A. Which domains should be included in a core set for endpoints in ankylosing spondylitis? Introduction to the ankylosing spondylitis module of OMERACT IV. J Rheumatol. 1999 Apr;26(4):945–947. [PubMed] [Google Scholar]
  17. van der Heijde D., van der Linden S., Bellamy N., Calin A., Dougados M., Khan M. A. Which domains should be included in a core set for endpoints in ankylosing spondylitis? Introduction to the ankylosing spondylitis module of OMERACT IV. J Rheumatol. 1999 Apr;26(4):945–947. [PubMed] [Google Scholar]
  18. van der Heijde D., van der Linden S., Dougados M., Bellamy N., Russell A. S., Edmonds J. Ankylosing spondylitis: plenary discussion and results of voting on selection of domains and some specific instruments. J Rheumatol. 1999 Apr;26(4):1003–1005. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES